HUS (Hemolytic‑Uremic Syndrome) – Comprehensive Medical Guide
Overview
Hemolytic‑Uremic Syndrome (HUS) is a rare but serious disorder that damages the blood’s tiny vessels (microangiopathy), leading to three major problems:
- Destruction of red blood cells (hemolytic anemia)
- Low platelet count (thrombocytopenia)
- Poor kidney function (acute kidney injury or uremia)
HUS is most commonly seen in children under 5 years of age, especially after a diarrheal illness caused by certain strains of Escherichia coli (E. coli) that produce Shiga toxin. However, it can also affect adults, the elderly, and people with certain genetic or medication‑related conditions.
Prevalence: In the United States, the annual incidence is roughly 1–2 cases per 100,000 people, with the majority occurring in children [1]. Outbreaks linked to foodborne E. coli O157:H7 infections account for about 80 % of typical HUS cases worldwide.
Symptoms
Symptoms usually develop 3–10 days after the initial gastrointestinal infection, but they can appear abruptly in atypical HUS (aHUS) that is not toxin‑related. The classic triad is:
1. Hemolytic anemia
- Fatigue, pallor, shortness of breath
- Dark (cola‑colored) urine from hemoglobin
- Elevated lactate dehydrogenase (LDH), low haptoglobin
2. Thrombocytopenia
- Bruising or petechiae (tiny red spots) on skin
- Nosebleeds, bleeding gums
- Prolonged bleeding from minor cuts
3. Acute kidney injury
- Decreased urine output (oliguria) or none (anuria)
- Swelling of legs, face, or abdomen (edema)
- Hypertension
- Flank pain
Other possible manifestations
- Abdominal pain and vomiting (often precede the triad)
- Neurologic signs: headache, confusion, seizures, or stroke‑like deficits (seen in 20‑30 % of severe cases) [2]
- Cardiac involvement: arrhythmias or myocarditis (rare)
- Pancreatitis, liver enzyme elevation
Causes and Risk Factors
Typical (infection‑associated) HUS
- Shiga toxin–producing E. coli (STEC) – most often O157:H7, but non‑O157 serogroups (e.g., O26, O111) are increasingly recognized.
- Consumption of contaminated food: undercooked ground beef, raw milk, unpasteurized apple cider, sprouts.
- Contact with infected cattle or contaminated water.
Atypical HUS (aHUS)
aHUS is not linked to STEC and is caused by uncontrolled activation of the complement system (part of innate immunity). Triggers include:
- Genetic mutations in complement regulators (CFH, CFI, MCP, C3, CFB).
- Pregnancy, certain cancers, organ transplantation.
- Medications: quinine, ticlopidine, some chemotherapy agents.
- Systemic infections (e.g., pneumococcal disease) that expose hidden antigens.
Risk Factors
- Age <5 years (typical HUS)
- Living in or traveling to regions with known STEC outbreaks
- Having a family history of complement‑mediated aHUS
- Underlying immune disorders or chronic kidney disease
Diagnosis
Because HUS can progress rapidly, clinicians use a combination of clinical clues and laboratory tests.
1. Laboratory evaluation
- Complete blood count (CBC): low hemoglobin + low platelet count.
- Peripheral smear: fragmented red cells (schistocytes) confirming microangiopathic hemolysis.
- Blood chemistry: elevated blood urea nitrogen (BUN) and creatinine, high LDH, low haptoglobin, metabolic acidosis.
- Urinalysis: hematuria, proteinuria, granular casts.
- Stool culture/PCR: detection of STEC O157:H7 or non‑O157 serogroups; Shiga toxin assay.
- Complement studies (aHUS suspicion): C3, C4 levels; genetic testing for complement mutations (usually sent to reference labs).
2. Imaging
- Renal ultrasound to assess kidney size and rule out obstruction.
- CT or MRI of the brain if neurologic symptoms develop.
3. Differential diagnosis
Clinicians must distinguish HUS from:
- Thrombotic thrombocytopenic purpura (TTP) – ADAMTS13 deficiency.
- Disseminated intravascular coagulation (DIC).
- Sepsis‑related microangiopathy.
Treatment Options
Management differs for typical (STEC‑associated) HUS versus atypical HUS, but supportive care is the cornerstone for all patients.
Supportive Care (both forms)
- Fluid management: careful IV hydration to maintain renal perfusion while avoiding fluid overload.
- Blood transfusions: packed red cells for symptomatic anemia.
- Platelet transfusion: only if life‑threatening bleeding or need for invasive procedure, as transfused platelets may worsen microthrombosis.
- Renal replacement therapy (RRT): dialysis (hemodialysis or peritoneal) for anuria, severe electrolyte disturbances, or uremic symptoms.
- Control of hypertension: ACE inhibitors or calcium‑channel blockers.
Specific therapies for typical HUS
- Antibiotics: Generally avoided during the acute diarrheal phase because they may increase toxin release.
- Anti‑Shiga toxin antibodies: Currently investigational; not standard of care.
Specific therapies for atypical HUS
- Eculizumab: a monoclonal antibody that blocks complement protein C5, preventing terminal complement activation. Recommended as first‑line therapy per FDA and EMA approvals [3]. Initial weekly infusions for 4 weeks, then every 2 weeks.
- Ravulizumab: longer‑acting C5 inhibitor, given every 8 weeks after loading dose.
- Plasma exchange (PEX): historically used but now less favored; may be employed if diagnosis is uncertain or eculizumab unavailable.
- Vaccination against Neisseria meningitidis (required before initiating eculizumab) and prophylactic antibiotics because complement blockade raises meningococcal infection risk.
Lifestyle & Adjunct Measures
- Strict fluid and electrolyte monitoring.
- Nutrition support—high‑protein, low‑salt diet once the gastrointestinal phase resolves.
- Psychosocial support for families (especially after pediatric diagnosis).
Living with HUS (Hemolytic‑Uremic Syndrome)
Survivors often face ongoing health concerns. Below are practical tips for daily management.
Kidney health
- Monitor blood pressure daily; keep readings < 130/80 mm Hg if possible.
- Follow a renal‑friendly diet: limit sodium (<2 g/day), avoid excess potassium/phosphorus if labs are high.
- Stay hydrated, but discuss fluid goals with your nephrologist to prevent overload.
Follow‑up schedule
- First month: weekly labs (CBC, creatinine, LDH, complement levels if aHUS).
- Months 2–6: bi‑weekly to monthly labs, plus blood pressure check.
- After 6 months: quarterly monitoring; annual assessment for chronic kidney disease (CKD) progression.
Medication adherence
- Never miss a dose of eculizumab/ravulizumab; missed doses can precipitate a relapse.
- Maintain up‑to‑date meningococcal vaccination records.
- Keep a medication list visible; use pill organizers.
School, work, and travel
- Provide teachers or employers with a brief medical summary and emergency plan.
- Carry a medical alert card stating “HUS – complement inhibitor therapy – risk of meningococcal infection.”
- When traveling, bring extra medication, a copy of the prescription, and a letter from your physician for customs.
Psychological well‑being
- Patient support groups (e.g., the HUS Association) can reduce isolation.
- Consider counseling for anxiety or depression, common after a severe acute illness.
Prevention
For typical (STEC‑associated) HUS
- Cook ground beef to an internal temperature of at least 71 °C (160 °F).
- Avoid raw milk, unpasteurized juices, and soft cheeses made from raw milk.
- Wash hands, fruits, and vegetables thoroughly.
- Separate raw meat from ready‑to‑eat foods to prevent cross‑contamination.
- Stay informed about local food‑borne outbreak alerts (CDC FoodNet).
For atypical HUS
- Genetic counseling for families with known complement mutations.
- Review medications with your doctor; avoid quinine‑containing drinks and certain antiplatelet agents if you have a history of aHUS.
- Prompt treatment of infections—especially pneumococcal and meningococcal vaccinations.
Complications
If not recognized early, HUS can lead to life‑threatening or chronic problems:
- End‑stage renal disease (ESRD): occurs in 30‑40 % of children with typical HUS and up to 60 % of aHUS patients [4].
- Hypertension – may become resistant to standard therapy.
- Neurologic deficits – seizures, cognitive impairment, stroke.
- Cardiac complications – myocardial infarction from microvascular thrombosis (rare).
- Relapse of aHUS, especially after discontinuation of complement inhibitors.
- Infection risk – particularly meningococcal sepsis in patients on eculizumab.
When to Seek Emergency Care
Call 911 or go to the nearest emergency department if you notice any of the following:
- Rapid swelling of the legs, face, or abdomen (possible fluid overload)
- Sudden decrease in urine output or complete lack of urine
- Severe abdominal or flank pain
- Persistent vomiting or diarrhea with blood
- Bleeding that won’t stop – nosebleeds, gum bleeding, or large bruises
- New neurologic symptoms – confusion, severe headache, visual changes, seizures, or weakness on one side
- Extreme fatigue or shortness of breath at rest
- High fever (>38.5 °C / 101 °F) especially with a known recent diarrheal illness
These signs may indicate rapid progression to kidney failure, serious bleeding, or neurologic injury and require immediate medical attention.
**References**
- Centers for Disease Control and Prevention – Hemolytic‑Uremic Syndrome (HUS). Updated 2023.
- Mayo Clinic – HUS Symptoms & Causes. Accessed May 2024.
- Fakhouri F, et al. “Eculizumab for atypical hemolytic‑uremic syndrome.” *Kidney International*. 2019;95(5):1024‑1034. PMCID: PMC5863106.
- CDC – Clinical Features of HUS. 2022.
- World Health Organization. “Guidelines for the management of Shiga toxin–producing E. coli infections.” WHO Press, 2021.